The skincare industry has a story it tells very well. It is the story of the independent founder — the dermatologist who saw a gap, the chemist who wanted better, the woman who could not find a clean product and made her own. It is a story about mission, about science, about values.

It is also, in most cases, a story that stopped being true the moment a nine-figure acquisition cheque cleared.

This is not a cynical take. Acquisition does not automatically compromise product quality. The Ordinary's INCI lists are still transparent. CeraVe's ceramide science is still real. But consumers who make purchasing decisions based on a brand's perceived independence, founder-led ethos, or opposition to corporate beauty deserve to know who is actually cashing the revenue.

Here is the full picture.

The Four Conglomerates That Own Modern Skincare

Four companies — L'Oréal, Estée Lauder Companies, Unilever, and Shiseido — control the vast majority of the brands that dominate skincare conversation. Between them, they have spent billions of dollars acquiring brands that built their identities on being everything these conglomerates are not.

| Conglomerate | Key Skincare Acquisitions | Approx. Spend | |---|---|---| | L'Oréal | CeraVe, La Roche-Posay, Vichy, SkinCeuticals | $1.65B+ | | Estée Lauder | DECIEM / The Ordinary, Dr. Jart+, Clinique | $1.7B+ | | Unilever | Tatcha, Dermalogica, Kate Somerville, Murad, REN | $2B+ | | Shiseido | Drunk Elephant, Bare Minerals, NARS | $845M+ |

L'Oréal: The Dermatological Division

L'Oréal is the world's largest beauty company by revenue. Its Active Cosmetics Division — the division that houses the brands marketed as dermatologist-recommended and clinically validated — includes brands that most consumers do not associate with a single corporate parent.

CeraVe was founded in 2005 and acquired by L'Oréal in January 2017 for approximately USD $1.3 billion, in a deal that also included AcneFree and Ambi. The acquisition was announced publicly by L'Oréal and confirmed in their 2017 financial filings. CeraVe's "dermatologist-developed" positioning predates the acquisition and has been maintained and amplified under L'Oréal ownership.

La Roche-Posay has been a L'Oréal property since 1989 — longer than most of its current consumers have been alive. The brand's positioning as a dermatologist-recommended, pharmacy-distributed skincare line is a L'Oréal marketing strategy that has been in place for over three decades.

Vichy has been owned by L'Oréal since 1980. SkinCeuticals was acquired by L'Oréal in 2005 for approximately USD $350 million.

L'Oréal's Active Cosmetics Division reported revenue of approximately €4.3 billion in 2022. The division's growth has been driven substantially by the dermatologist recommendation channel — a channel that L'Oréal has invested heavily in cultivating through medical education programmes and dermatology partnerships.

"L'Oréal does not hide its ownership of these brands. The information is in every annual report. The question is whether consumers are looking."

Estée Lauder Companies: The Ordinary Is Not Ordinary Anymore

DECIEM was founded in Toronto in 2013 by Brandon Truaxe. The Ordinary became the company's flagship brand and one of the fastest-growing skincare brands in history, built explicitly on a rejection of luxury skincare pricing and a commitment to ingredient transparency.

In 2017, Estée Lauder Companies acquired a minority stake in DECIEM. Following the death of Brandon Truaxe in January 2019, Estée Lauder increased its involvement. In 2021, Estée Lauder acquired a majority stake, valuing DECIEM at approximately USD $2.2 billion. In June 2024, Estée Lauder completed its full acquisition of DECIEM for a total investment of USD $1.7 billion, bringing The Ordinary, NIOD, and the rest of the DECIEM portfolio fully under Estée Lauder ownership.

Estée Lauder also owns: Clinique (since 1968), Origins, Bobbi Brown, MAC Cosmetics, Aveda, Jo Malone London, Tom Ford Beauty, and Dr. Jart+ (acquired 2019).

The Ordinary's ingredient transparency is genuine and has been maintained under Estée Lauder ownership. The brand's pricing has remained low relative to the rest of the Estée Lauder portfolio. What has changed is the corporate context: the brand that positioned itself against luxury beauty is now a subsidiary of one of the world's largest luxury beauty conglomerates.

Unilever: The Prestige Acquisitions

Unilever is better known for Dove, Vaseline, and Lynx. Its prestige beauty acquisitions tell a different story.

Tatcha was acquired by Unilever in June 2019 for a reported price approaching USD $500 million, according to multiple industry sources including WWD and Allure. Tatcha was founded in 2009 by Vicky Tsai and built its brand identity around Japanese beauty rituals, "clean" ingredients, and a premium positioning that justified prices of $68 for a cleanser and $185 for a moisturiser. The brand's "independent luxury" narrative was central to its consumer appeal.

Unilever also owns: Dermalogica (acquired 2015 for approximately USD $1 billion), Kate Somerville, Murad, and REN Clean Skincare.

The Tatcha acquisition is particularly instructive. A brand that built its identity on artisanal Japanese sourcing, founder-led storytelling, and premium independence is now a product line within a conglomerate whose other personal care brands include Radox and Brylcreem.

Shiseido: The Clean Beauty Acquisition That Went Wrong

Drunk Elephant was founded in 2012 by Tiffany Masterson and acquired by Shiseido in October 2019 for USD $845 million — at the time, one of the largest acquisitions in prestige skincare history. The brand's "clean compatible" philosophy and its distinctive colourful packaging had made it one of the most talked-about skincare brands of the 2010s.

The acquisition has not gone as planned. Shiseido reported its steepest operating profit loss in decades in its 2025 financial results, writing down the value of the Drunk Elephant acquisition significantly. Drunk Elephant sales declined in 2025 as the brand's cultural moment faded and consumers questioned whether the "clean compatible" positioning had ever been meaningfully different from conventional skincare.

"Drunk Elephant was acquired for $845 million on the basis of a marketing concept. The INCI lists never supported the premium."

The Contract Manufacturing Reality

Beyond ownership, there is a second structural fact that the industry does not advertise: most skincare brands do not manufacture their own products.

The majority of skincare products — across price points, brand identities, and ownership structures — are manufactured by a relatively small number of contract manufacturers. Companies like Cosmax and Kolmar Korea produce formulations for multiple brands simultaneously. A "proprietary formula" is, in many cases, a white-label base with minor modifications to active concentrations, fragrance, or preservative system.

This is not fraud. It is standard industry practice. But it means that a $200 serum and a $20 serum may share a contract manufacturer, a base formula, and a nearly identical INCI list — differentiated primarily by packaging, marketing spend, and retail channel.

The Cost of Goods Reality

The retail price of a skincare product is not a reliable indicator of its formulation quality. Industry standard cost-of-goods ratios for prestige skincare typically sit between 10–20% of retail price. A $50 serum commonly has a cost of goods — ingredients, packaging, manufacturing — of $5–10. The remainder covers marketing, retailer margin, and brand overhead.

This is not unique to skincare. It is the economics of branded consumer goods. The relevant question for consumers is whether the premium is justified by the formulation — and the INCI list is the only document that can answer that.

What This Means for Your Purchasing Decisions

Corporate ownership does not automatically make a product worse. The Ordinary's formulations are still transparent. CeraVe's clinical evidence is still real. Tatcha's ingredients are still what they say they are.

What changes is the context. When a brand's entire identity is built on independence, founder values, or opposition to corporate beauty, and that brand is a wholly-owned subsidiary of a multi-billion-dollar conglomerate, the identity is a marketing construct — not a description of reality.

The INCI list remains the most reliable document attached to any skincare product. It tells you what is in the formula. Corporate filings tell you who profits from your purchase. Neither is secret. Both are worth knowing.

---

*All acquisition prices cited in this article are sourced from publicly available corporate press releases, verified industry reporting (WWD, Business of Fashion, Allure, Glossy), and official company filings. Where exact terms were not disclosed, reported estimates from multiple industry sources are used and labelled as such.*